Precigen (PGEN) AI Stock Analysis

• Market Cap: $1.19B
• Dividend Yield: N/A
• Average Volume (3M): 4.79M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.91
• Revenue Growth: -1.12%
• EPS Growth: 20.77%
• Country: US
• Employees: 143
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.09
• Shares Outstanding: 297,972,930
• 10 Day Avg. Volume: 3,924,098
• 30 Day Avg. Volume: 4,790,263
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.33
• Enterprise Value/Revenue: 91.53
• Enterprise Value/Gross Profit: -1.14K
• Enterprise Value/Ebitda: -3.26
• 1Y Price Target: $8.25
• Price Target Upside: 110.46% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): -0.4
• Revenue Forecast (FY): $13.43M

• Rating: 52 Neutral
• Price Target: $4.00 ▲(2.04% Upside)

Precigen's overall stock score is primarily impacted by its weak financial performance, characterized by negative margins and equity. Despite this, the stock's technical indicators show bullish momentum, providing some positive outlook. However, the negative P/E ratio and lack of dividend yield contribute to a low valuation score.

Positive Factors

FDA Approval of PAPZIMEOS

The FDA approval of PAPZIMEOS provides Precigen with a unique market position as the first approved therapy for recurrent respiratory papillomatosis, potentially driving long-term revenue growth and enhancing its competitive advantage in the biotechnology sector.

Strategic Partnerships

Strategic partnerships with major pharmaceutical companies offer Precigen access to broader markets and resources, potentially accelerating research and development efforts and enhancing revenue streams through milestone payments and royalties.

Innovative Technology Platforms

Precigen's proprietary technology platforms, such as UltraCar-T, position the company at the forefront of gene and cell therapy innovation, providing a strong foundation for developing transformative treatments and sustaining long-term competitive advantage.

Negative Factors

Negative Financial Performance

The company's ongoing financial challenges, including negative margins and equity, indicate a high-risk profile and potential solvency issues, which could hinder long-term growth and operational stability.

Cash Flow Concerns

Precigen's negative operating cash flow and declining free cash flow growth highlight cash generation issues that may impact its ability to fund operations and invest in future growth, posing risks to its financial health.

Balance Sheet Instability

The negative stockholders' equity and debt-to-equity ratio suggest significant balance sheet instability, raising concerns about Precigen's financial resilience and its ability to withstand economic fluctuations or financial stress.

Precigen Business Overview & Revenue Model

Company Description

Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Ares Trading S.A.; Oragenics, Inc.; Castle Creek Biosciences, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.

How the Company Makes Money

Precigen generates revenue through a combination of product sales, partnerships, and collaborations with pharmaceutical companies. The company derives income from licensing its proprietary technology platforms to other firms, as well as from milestone payments and royalties associated with the development and commercialization of its therapies. Significant partnerships, particularly those with major pharmaceutical players, enhance its revenue potential by providing access to broader markets and resources for research and development. Additionally, Precigen may receive funding through government grants and contracts aimed at advancing innovative therapies.

Precigen Financial Statement Overview

Summary

Precigen's financial performance is severely weak, with declining revenues, negative profit margins, and financial instability. The income statement shows significant operational losses, the balance sheet reflects negative equity and high liabilities, and cash flow analysis indicates reliance on external financing.

Income Statement

Precigen's income statement reflects significant challenges with declining revenues and negative profit margins. The gross profit margin is negative at -2.17% TTM, indicating costs exceed sales. The net profit margin is also severely negative at -3728.79% TTM, showing substantial losses. Revenue has decreased drastically over recent periods, with a TTM revenue growth rate of -32.56%. EBIT and EBITDA margins are also negative, highlighting ongoing operational inefficiencies.

Balance Sheet

The balance sheet shows financial instability, with negative stockholders' equity of -$14.06 million TTM, indicating liabilities exceed assets. The debt-to-equity ratio isn't applicable due to negative equity, but the presence of high total liabilities of $142.85 million suggests significant leverage. The equity ratio is negative, further emphasizing the weak financial position. Return on equity is not applicable due to negative equity.

Cash Flow

Cash flow analysis shows continuous negative free cash flow, with a slight improvement in operating cash flow. Free cash flow growth rate is slightly positive at 1.95% TTM, but remains negative overall at -$75.26 million. The operating cash flow to net income ratio is 0.45 TTM, reflecting some operational cash generation despite losses. However, the company is heavily reliant on financing activities for cash inflow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.34M	3.92M	6.22M	26.91M	14.27M	103.18M
Gross Profit	-348.00K	-342.00K	-4.74M	20.57M	45.49M	47.66M
EBITDA	-121.97M	-123.50M	-89.23M	-66.00M	-84.07M	-70.41M
Net Income	-124.50M	-126.23M	-95.90M	28.32M	-92.17M	-170.52M
Balance Sheet
Total Assets	101.90M	145.27M	151.04M	215.98M	359.86M	314.59M
Cash, Cash Equivalents and Short-Term Investments	59.75M	97.91M	62.85M	55.95M	108.66M	100.12M
Total Debt	5.15M	5.50M	7.10M	51.42M	190.07M	182.28M
Total Liabilities	107.79M	106.75M	32.55M	89.72M	252.51M	247.41M
Stockholders Equity	-36.78M	66.73M	118.50M	126.26M	107.35M	67.17M
Cash Flow
Free Cash Flow	-68.19M	-76.76M	-68.47M	-69.97M	-63.02M	-84.55M
Operating Cash Flow	-66.28M	-68.17M	-66.93M	-65.05M	-55.77M	-77.02M
Investing Cash Flow	-59.71M	-20.71M	-3.09M	226.42M	-74.54M	27.78M
Financing Cash Flow	108.09M	110.58M	29.59M	-155.29M	121.19M	32.70M

Precigen Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3.92
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PGEN, the sentiment is Positive. The current price of 3.92 is above the 20-day moving average (MA) of 3.88, above the 50-day MA of 3.85, and above the 200-day MA of 2.24, indicating a bullish trend. The MACD of 0.12 indicates Positive momentum. The RSI at 52.05 is Neutral, neither overbought nor oversold. The STOCH value of 14.96 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PGEN.

Precigen Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MDXG	68 Neutral	$1.14B	28.17	19.44%	―	14.77%	-58.90%
PRAX	58 Neutral	$4.15B	―	-75.20%	―	364.98%	-25.33%
IMNM	55 Neutral	$1.34B	―	-81.20%	―	16.74%	59.89%
PGEN	52 Neutral	$1.19B	―	-668.03%	―	-1.12%	20.77%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
WVE	49 Neutral	$1.28B	―	-171.41%	―	-14.98%	-51.76%
ORIC	43 Neutral	$1.19B	―	-43.82%	―	―	-7.33%

Precigen Corporate Events

Precigen Converts Preferred Stock to Common Shares

On September 15, 2025, Precigen, Inc. saw the conversion of 79,000 shares of its 8.00% Series A Convertible Perpetual Preferred Stock into 54,937,411 shares of common stock. This conversion was executed under the terms of the company’s Amended and Restated Articles of Incorporation, with the common stock issued on September 17, 2025. The transaction was conducted under an exemption from registration, involving an exchange with existing security holders without any commission or remuneration for solicitation.

The most recent analyst rating on (PGEN) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Precigen stock, see the PGEN Stock Forecast page.

Precigen Secures $125M Loan for PAPZIMEOS Expansion

On September 3, 2025, Precigen, Inc. announced a loan agreement with Pharmakon Advisors, LP, securing a 5-year senior secured term loan facility of up to $125 million. This non-dilutive financing, with an initial $100 million funded at closing, aims to support the commercialization of PAPZIMEOS, a novel immunotherapy, in the US and potentially expand into international markets. The agreement strengthens Precigen’s financial position, enabling it to pursue pediatric and other HPV-related indications, and is expected to drive significant growth, positioning the company as a leading biopharma innovator.

The most recent analyst rating on (PGEN) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Precigen stock, see the PGEN Stock Forecast page.

Precigen Enters Commercial Supply Agreement with Catalent

On August 13, 2025, Precigen, Inc. entered into a Commercial Supply Agreement with Catalent Maryland, Inc. This agreement mandates Catalent to provide various services including analytical, development, processing, validation, and product maintenance for Precigen’s product, PAPIZEMOS. The agreement establishes Catalent as the exclusive provider for Precigen’s commercial fill and finish manufacturing needs for PAPIZEMOS, with terms including annual price adjustments and a minimum purchase requirement. The initial term of the agreement is three years, with automatic one-year renewals unless terminated by either party. This collaboration is expected to streamline Precigen’s manufacturing processes and potentially enhance its market positioning by ensuring consistent product supply.

The most recent analyst rating on (PGEN) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Precigen stock, see the PGEN Stock Forecast page.

Precigen’s PAPZIMEOS Receives FDA Approval for RRP

On August 18, 2025, Precigen, Inc. announced that its product PAPZIMEOS received FDA approval as the first and only therapy for adults with recurrent respiratory papillomatosis (RRP), a rare and debilitating disease. This approval positions PAPZIMEOS as a potential standard-of-care treatment, offering a new paradigm for managing RRP, which was previously treated mainly through surgical interventions. The approval is expected to significantly impact Precigen’s market positioning and provide a new therapeutic option for the estimated 27,000 adult RRP patients in the US.

The most recent analyst rating on (PGEN) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Precigen stock, see the PGEN Stock Forecast page.

Precigen, Inc. Reports Q2 2025 Earnings and Strategic Focus

Precigen, Inc. is a biopharmaceutical company focused on advancing gene and cell therapies to address significant unmet medical needs, primarily in the fields of immuno-oncology, autoimmune disorders, and infectious diseases. The company recently released its earnings report for the second quarter of 2025, highlighting ongoing financial challenges and strategic shifts.